

Surface Logix, Inc. Company Profile

Surface Logix, Inc. uses its expertise in biophysical chemistry to create and develop novel small molecule drugs (NCEs) that target specific tissues and organ systems. The company is advancing multiple internal programs in the areas of metabolic, cardiovascular and other diseases. All of our drug candidates have been discovered and developed internally, using our proprietary chemistry platform – the Pharmacomer™ Technology Platform.

Pipeline

Indication	Target	Discovery	Preclinical	IND Prep/Sub	Phase 1	Phase 2
Metabolic Disease	eMTP	SLx-4090 Phase 2				
Hypertension	PDE5	SLx-2101 Phase 2				
Raynaud's Syndrome	PDE5	SLx-2101 Phase 2				
Oncology/ Fibrosis	ROCK	SLx-2119				
Metabolic Disease	eMTP					
Metabolic Disease	enteric					
Metabolic / Inflammation	enteric					

SLx-4090 is a first-in-class inhibitor of enterocytic microsomal triglyceride transfer protein (MTP), designed to treat metabolic and cardiovascular disease while overcoming the toxicity issues inherent in systemic MTP inhibition. Taken orally, SLx-4090 targets MTP only in enterocytes, thus blocking a key step in the adsorption of dietary triglycerides and cholesterol into the lymphatic circulation. Because SLx-4090 does not enter the systemic circulation, it avoids the mechanistic toxicities of MTP inhibition, such as fatty liver, seen with other MTP inhibitors. Results obtained to date indicate that SLx-4090 is active in dyslipidemia, diabetes and obesity. In a recently completed Phase 2a study in dyslipidemic patients, SLx-4090 demonstrated reductions in postprandial triglycerides and fasting LDL-cholesterol, as well as weight and markers of glucose control. Surface Logix plans to initiate a Phase 2b study with SLx-4090 in early 2009.

SLx-2101 is an oral, potent, selective, fast onset, long-acting PDE5 inhibitor designed specifically to expand the therapeutic potential of PDE5 inhibition beyond erectile dysfunction into larger cardiovascular (CV) markets. SLx-2101 is uniquely positioned among the known PDE5 inhibitors to address cardiovascular disease because, compared to currently marketed PDE5 drugs, SLx-2101 preferentially distributes into cardiovascular tissue. SLx-2101 achieves sustained plasma levels and a long duration of action, without showing accumulation upon repeat dosing. This superior product profile allows for daily or on demand dosing with a predictable response in a number of CV disorders that currently marketed PDE5 therapies cannot adequately treat. Phase 2a studies in hypertension and in Raynaud's syndrome have been successfully completed.

SLx-2119 is a selective, orally available inhibitor of Rho kinase 2 (ROCK2). SLx-2119's selectivity for ROCK2 eliminates the acute hemodynamic effects seen with dual ROCK1/ROCK2 inhibition (e.g., fasudil). Currently in IND preparation stage, SLx-2119 has shown significant promise in cancer xenograft models and in preclinical models of fibrosis.

Drug Development Approach

Surface Logix's Pharmacomer™ Technology Platform allows the rapid identification of NCE development candidates starting from a pharmacophore that has PK or physico-chemical liabilities. Application of the technology results in improved functional performance, and the unique chemical nature of Pharmacomers™ enables Surface Logix to establish new intellectual property (IP) positions on these NCEs.

The Pharmacomer™ Technology Platform consists of:

- Small (<150 MW), unique functional groups, called Pharmacomers™, which can predictably improve the PK and PD profile of drugs
- Pharmacomer functional indices determined experimentally using proprietary surface-based assays to predict the impact of individual Pharmacomers™ on the PK and/or PD profiles of drugs
- *In silico* measurements that are used to design and characterize the physicochemical and biological properties of Pharmacomers

In particular, Pharmacomers™:

- Prevent the undesired interactions of drugs with blood and tissue proteins
- Improve the solubility and permeability of drugs;
- Allow control over the gastrointestinal absorption of drugs;
- Enhance the desired molecular interactions to improve the potency and selectivity of drugs

Intellectual Property

Our broad intellectual property position comprises over 27 US & foreign patents and 133 pending applications. All Surface Logix compounds currently in preclinical/clinical development are covered by composition of matter patents.

Team

Surface Logix has assembled an experienced management team, strong financial resources and world class scientists to build a pipeline of optimized compounds through the use of the Pharmacomer™ Technology Platform. The Surface Logix management team represents over 130 years of combined pharmaceutical industry experience, with extensive experience in drug discovery, development, business development and commercialization.

Senior Management:

Keith Dionne, PhD, *President and CEO*
Warwick Tong, MB, ChB, MPP, *SVP, Development*
Leland Webster, PhD, MBA, *VP, Corporate Development*
Bridget McCarthy, PhD, *VP, Chemistry*
John Ferkany, PhD, *VP, Development*

Paul Sweetnam, PhD, *Chief Scientific Officer*
Winston Henderson, *VP, General Counsel*
Jim Ellis, PhD, *VP, Preclinical Research*
Enoch Kim, PhD, *VP, New Drug Discovery*
Olivier Schueller, PhD, *VP, Chemical Development*

Board of Directors:

Steven Gillis, PhD, *Chairman, Surface Logix; Partner, Arch Venture Partners*
Keith Dionne, PhD, *President and CEO, Surface Logix*
George Whitesides, PhD, *Co-Founder, Surface Logix*
Marc Rubin, MD, *President & CEO of Titan Pharmaceuticals*

Bryan Roberts, PhD, *Partner, Venrock Associates*
W. James O'Shea, *former President & COO, Sepracor*

Scientific Advisors:

George Whitesides, PhD, *Harvard University*
Ron Borchardt, PhD, *University of Kansas*
Fred Vinick, PhD, *formerly SVP of Drug Discovery, Genzyme*

John Deutch, PhD, *MIT*
Willard Welch, PhD, *Pfizer Sr. Research Fellow (ret.)*